Duchenne Muscular Dystrophy (DMD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

Duchenne Muscular Dystrophy (DMD) Market Outlook

Thelansis’s “Duchenne Muscular Dystrophy (DMD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Duchenne Muscular Dystrophy (DMD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Duchenne Muscular Dystrophy (DMD) Overview

Duchenne muscular dystrophy (DMD) is a severe X-linked recessive disorder caused by DMD gene mutations abolishing dystrophin production, causing muscle membrane fragility, chronic inflammation, and fibrofatty muscle degeneration. Boys present with proximal weakness, Gowers sign, and calf pseudohypertrophy, progressing to loss of ambulation, respiratory insufficiency, and fatal cardiomyopathy. Diagnosis requires elevated creatine kinase, immunostaining, or genetic sequencing. Corticosteroids like deflazacort and vamorolone remain foundational. Targeted therapies include exon-skipping antisense oligonucleotides for specific mutations and the AAV-based gene therapy delandistrogene moxeparvovec. Management in 2026 also utilizes the approved HDAC inhibitor givinostat for patients aged six months and older to directly mitigate downstream fibrofatty muscle transformation. Proactive cardiac surveillance, non-invasive ventilation, and physical therapy are mandatory components of long-term care.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Duchenne Muscular Dystrophy (DMD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036